参麦注射液辅助治疗对肺尘埃沉着病患者肺部纤维化相关指标的改善作用(1)
[摘要]目的 探讨分析参麦注射液辅助治疗对肺尘埃沉着病患者肺部纤维化相关指标的改善作用。方法 选取2017年3月～2019年3月韶关市职业病防治院收治的肺尘埃沉着病患者78例作为研究对象，采用随机数字表法将其分为试验组(n=39)和参照组(n=39)。参照组患者采用解痉、止咳、化痰、吸氧、消炎、补液等肺尘埃沉着病的常规对症支持以及汉防己甲素片治疗，试验组患者在此基础上加以参麦注射液进行辅助治疗。治疗后，对比两组患者的人Ⅲ型前胶原肽(PⅢP)、Ⅳ型胶原(CⅣ)及Ⅰ型前胶原羧基端肽(PⅠCP)肺部纤维化相关指标的改善情况，并统计患者的临床疗效。结果 治疗前，两组患者的PⅢP、CⅣ及PⅠCP肺部纤维化指标比较，差异无统计学意义(P>0.05);治疗后，两组患者的PⅢP、CⅣ及PⅠCP肺部纤维化指标均低于治疗前，差异有统计学意义(P<0.05)，且试验组患者的血清PⅢP、CⅣ及PⅠCP肺部纤维化指标均低于参照组，差异有统计学意义(P<0.05);试验组患者治疗的总有效率为93.02%，高于參照组的74.36%，差异有统计学意义(P<0.05)。结论 肺尘埃沉着病患者应用参麦注射液进行辅助治疗，能有效改善肺部纤维化情况，提高临床疗效，值得临床推广。
[关键词]参麦注射液;辅助治疗;肺尘埃沉着病;肺部纤维化;治疗效果
[中图分类号] R562.22 [文献标识码] A [文章编号] 1674-4721(2020)5(b)-0058-03
Effect of Shenmai Injection on the improvement of pulmonary fibrosis related indexes in patients with pneumoconiosis
YANG Li-qun1 HUANG Sheng2 DU Ping1
1. The First Department of Rehabilitation， Hospital of Occupational Disease Prevention and Control in Shaoguan City， Guangdong Province， Shaoguan 512000， China; 2. Department of Internal Medicine， the second People′s Hospital of Northern Guangdong in Shaoguan City， Guangdong Province Shaoguan 512000， China
[Abstract] Objective To investigate the effect of Shenmai Injection on pulmonary fibrosis in patients with pneumoconiosis. Methods A total of 78 patients with pneumoconiosis treated in Hospital of Occupational Disease Prevention and Control in Shaoguan City from March 2017 to March 2019 were selected as the subjects. The patients were divided into experimental group (n=39) and reference group (n=39) by random digital table method. The patients in reference group adopted the routine symptomatic support of spasmolytic， antitussive， expectorant， oxygen-absorbing， anti-inflammatory， fluid infusion and other pneumoconiosis， and the treatment of tetrandrine tablets， and the patients in the experimental group were treated with Shenmai Injection. After treatment， the improvement of pulmonary fibrosis related indexes such as human type Ⅲ procollagen peptide(PⅢP)， type Ⅳ collagen (CⅣ) and type Ⅰ procollagen carboxy terminal peptide (PⅠCP) were compared between the two groups， and the clinical efficacy of the two groups was counted. Results Before treatment， there were no significant differences in pulmonary fibrosis indexes such as PⅢP， CⅣ and PⅠCP between the two groups (P>0.05). After treatment， the pulmonary fibrosis indexes such as PⅢP， CⅣ and PⅠCP in the two groups were lower than those before treatment (P<0.05)， and the pulmonary fibrosis indexes such as CⅣ and PⅠCP in the experimental group were lower than those in the control group (P<0.05). The total effective rate of treatment in the experimental group was 93.02%， which was higher than that in the control group (74.36%) (P<0.05). Conclusion Shenmai Injection can effectively improve pulmonary fibrosis， delay the development of pneumoconiosis and improve the clinical effect., 百拇医药(杨丽群 黄胜 杜平)
[关键词]参麦注射液;辅助治疗;肺尘埃沉着病;肺部纤维化;治疗效果
[中图分类号] R562.22 [文献标识码] A [文章编号] 1674-4721(2020)5(b)-0058-03
Effect of Shenmai Injection on the improvement of pulmonary fibrosis related indexes in patients with pneumoconiosis
YANG Li-qun1 HUANG Sheng2 DU Ping1
1. The First Department of Rehabilitation， Hospital of Occupational Disease Prevention and Control in Shaoguan City， Guangdong Province， Shaoguan 512000， China; 2. Department of Internal Medicine， the second People′s Hospital of Northern Guangdong in Shaoguan City， Guangdong Province Shaoguan 512000， China
[Abstract] Objective To investigate the effect of Shenmai Injection on pulmonary fibrosis in patients with pneumoconiosis. Methods A total of 78 patients with pneumoconiosis treated in Hospital of Occupational Disease Prevention and Control in Shaoguan City from March 2017 to March 2019 were selected as the subjects. The patients were divided into experimental group (n=39) and reference group (n=39) by random digital table method. The patients in reference group adopted the routine symptomatic support of spasmolytic， antitussive， expectorant， oxygen-absorbing， anti-inflammatory， fluid infusion and other pneumoconiosis， and the treatment of tetrandrine tablets， and the patients in the experimental group were treated with Shenmai Injection. After treatment， the improvement of pulmonary fibrosis related indexes such as human type Ⅲ procollagen peptide(PⅢP)， type Ⅳ collagen (CⅣ) and type Ⅰ procollagen carboxy terminal peptide (PⅠCP) were compared between the two groups， and the clinical efficacy of the two groups was counted. Results Before treatment， there were no significant differences in pulmonary fibrosis indexes such as PⅢP， CⅣ and PⅠCP between the two groups (P>0.05). After treatment， the pulmonary fibrosis indexes such as PⅢP， CⅣ and PⅠCP in the two groups were lower than those before treatment (P<0.05)， and the pulmonary fibrosis indexes such as CⅣ and PⅠCP in the experimental group were lower than those in the control group (P<0.05). The total effective rate of treatment in the experimental group was 93.02%， which was higher than that in the control group (74.36%) (P<0.05). Conclusion Shenmai Injection can effectively improve pulmonary fibrosis， delay the development of pneumoconiosis and improve the clinical effect., 百拇医药(杨丽群 黄胜 杜平)